Risk of Myocarditis and other AESI > Risk of COVID Hospitalizations (Part 25)
New research evidencing late onset vaxxed induced myocarditis and persistent myocardial injury lasting months after the last modRNA dose appears to falsify another official dogma that vaxxed induced myocarditis is only “transient.”
Forsdyke notes in his narrative review, published in the Federation of American Societies for Experimental Biology Journal, that the earliest evidence for long persistent and late onset vaxxed induced myocarditis emerged from case studies including any elderly man who developed myocarditis 3 months after his second dose of the primary series with no prior viral exposure and three patients undergoing cancer treatment who experienced myocarditis several weeks after their booster doses. Of course, this is only the tip of the iceberg.
A longitudinal multicenter retrospective study found, using the Myocarditis After COVID Vaccination (MACiV) study network of pediatric cardiologists (n = 433), that 89/307 pediatric patients who suffered COVID-19 vaccine-associated myocarditis after any of the first three doses reported persistent cardiac symptoms after a median follow-up time of 91 days (3 months) since their last dose while 98 patients evidenced persistent late gadolinium enhancement during their cardiac magnetic resonance follow up exam a median a median 159 days later (> 5 months) indicating myocardial scar formation. The cohort who suffered COVID-19 vaccine-associated myocarditis and the cohort who suffered multisystem inflammatory syndrome in children after infection were two different cohorts. Vaxxed injured patients were 67% white and 91% male while MIS-C patients were only 33% white, 66% male and a median of 3.3 years younger.
A clinical cohort study of adolescent and young adult patients suffering vaxx associated myopericarditis (n = 23), found that most patients had late gadolinium enhancement during their cardiac magnetic resonance exam at the longitudinal clinical follow up conducted at least 2 months after they were discharged from the hospital (n = 17) with the injury only resolving for 1 patient out of 11 patients during the first follow up done a median 108 days (>3.5 months) after their last dose and 1 out of 5 patients during the second follow up a median of 199 days (>6.5 months) after their last dose. The authors caution that patients with vaxx induced myocarditis/pericarditis need long term monitoring for signs of cardiac fibrosis (i.e. scarring).
As I mentioned in (Part 12) a retrospective PET Scan study (n = 1003) found evidence of subclinical myocarditis, through higher higher fluorine 18 fluorodeoxyglucose uptake in the myocardium than the unvaxxed cohort, 6 months after the second dose.